migraineFull doseFullEarly signal

Migraine days halved, and not because of the trip

The size of the reduction had nothing to do with how intense the experience was.

2021Published
Exploratory double-blind placebo-controlled crossover studyStudy type
10 peopleSample
What our evidence ratings mean

What they did

Ten adults with migraine received oral psilocybin and placebo in two sessions two weeks apart, keeping headache diaries throughout.

What they found

Weekly migraine days fell by 1.65 after psilocybin against 0.15 after placebo. The size of the reduction was not correlated with the intensity of the acute psychedelic effects.

1.65fewer migraine days per week
No linkto psychedelic intensity

Worth knowing

Ten people. The decoupling from subjective intensity is the genuinely interesting part, since it suggests a mechanism separate from the experience itself, but a sample this small cannot establish that.

Schindler et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics, 2021.

Read the source

Keep reading

eating disordersTwenty-one women with anorexia, and symptoms that improved for a yearOCDOne small trial is the entire case for psilocybin and OCDcluster headacheCluster headaches dropped on psilocybin, but not significantly

We include the trials that missed their endpoints alongside the ones that hit. A shelf that only holds good news is a marketing page, not a library.

Browse the library

Microdosing 8Depression 9Anxiety 6Addiction 9Cognition 6Ageing and injury 3Brain and plasticity 7Other conditions 9Safety 6All research 63

For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.